<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149565">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765088</url>
  </required_header>
  <id_info>
    <org_study_id>CSNO2012001</org_study_id>
    <nct_id>NCT01765088</nct_id>
  </id_info>
  <brief_title>A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas</brief_title>
  <official_title>A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to help determine whether the addition of
      Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ)
      in vivo and vitro,  when given along with temozolomide during the monthly cycles that follow
      radiation, is able to delay tumor growth, shrink tumors, or impact how long people with
      newly diagnosed high-grade glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to help determine whether the addition of
      Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ)
      in vivo and vitro,  when given along with temozolomide during the monthly cycles that follow
      radiation, is able to delay tumor growth, shrink tumors, or impact how long people with
      newly diagnosed high-grade glioma. Four weeks after radiotherapy, newly diagnosed WHO III-IV
      glioma patients will be randomised into two groups: TMZ group or TMZ+ α-IFN groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Over-all survival</measure>
    <time_frame>5-year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5-year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>temozolomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four weeks after radiotherapy, patients will be received  6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>temozolomide +α-IFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four weeks after radiotherapy, patients will be received  6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days</description>
    <arm_group_label>temozolomide</arm_group_label>
    <arm_group_label>temozolomide +α-IFN</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>α-IFN</intervention_name>
    <description>3mIU (3million) D1，3，5</description>
    <arm_group_label>temozolomide +α-IFN</arm_group_label>
    <other_name>INTRONA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years to 75 years

          -  newly diagnosed WHO III-IV glioma after operation and radiotherapy

          -  Karnofsky Performance Score ≥ 60

          -  Adequate bone marrow, liver and renal function

          -  Ability of subject to understand character and individual consequences    of  the
             clinical trial

          -  Written informed consent

          -  anticipating survival  ≥2 months

        Exclusion Criteria:

          -  Refusal to participate the study

          -  Known hypersensitivity or contraindication to temozolomide

          -  Incompletely radiation

          -  Pregnant or lactating females

          -  Malignant tumor other than brain tumor

          -  Contraindicated for MRI examination

          -  Unable to comply with the follow-up studies of this trial

          -  Purulent and chronic infected wounds

          -  Uncontrolled psychotic disorders or epilepsy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhong-ping CHEN, MD, PhD</last_name>
    <phone>+86-20-87343310</phone>
    <email>chenzhp@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng-cheng GUO, MD, PhD</last_name>
    <phone>+86-20-87343309</phone>
    <email>guochch@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong-ping Chen, MD,PhD</last_name>
      <phone>+86-20-87343310</phone>
      <email>chenzhp@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Cheng-cheng Guo, MD,PhD</last_name>
      <phone>+86-20-87343656</phone>
      <email>guochch@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhong-ping Chen, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongping Chen</investigator_full_name>
    <investigator_title>Professor and Chair, Department of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>High-grade glioma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Interferon-alpha</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon Alfa-2a</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
